CSL Share Price
Latest Financial ReportsCSL Profile on ASX website
Computershare's Investor Centre website
Financial Calendar 2016
16 Feb -
Half Year Results
17 Aug -
Full Year Results
12 Oct -
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
About the CSL Group
CSL Limited News
CSL Behring News
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email
CSL Share Price
CSL Share Price page to access the quote table and price chart.
CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.
With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 16,000 employees working in more than 30 countries.
CSL Announces Changes to the Board
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016.
AFSTYLA® (rFVIII-Single Chain) – FDA approval
CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
IDELVION® (rFIX-FP) - European Commission Approval
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
Seqirus Presentation to Investors/Analysts
Gordon Naylor, Russell Basser and Brent MacGregor deliver a presentation to investors and analysts during site tours at the Seqirus manufacturing facilities in Liverpool and Holly Springs.
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION®
(Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.
Half Year Result 2016 CSL Delivers Exceptional Performance
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1
NPAT grew 7% and EPS grew 9%, at constant currency2
Prior ASX Releases
View the ASX Archive